News

Researchers have developed a new way to stimulate the immune system to attack cancer cells, in a strategy that could work for many cancers.

Mount Sinai researchers developed a first-in-class cell-selective modRNA translation system that turns therapeutic genes on only in target cells.

Roswell Park scientists show that IL-36γ–armored CAR T cells reprogram neutrophils to trigger powerful immune responses against solid tumors.

A new modeling study suggests that current HPV vaccination programs reduce cervical cancer but are insufficient for elimination. Expanding coverage to more girls or including boys could achieve herd immunity and end HPV-related cancers.

Researchers have uncovered the immune signaling pathway responsible for rare mRNA vaccine–associated myocarditis and showed that inhibiting CXCL10 and IFN-gamma reduces heart inflammation in cell and animal models.

Targeting senescent cells with CAR T therapy restores gut epithelial renewal and protects against radiation-induced damage, offering a potential path to improve gut health in older adults and cancer patients.

Researchers used AI to pinpoint a previously overlooked mpox surface protein that human antibodies strongly target. When engineered and tested in mice, this single protein generated protective, neutralizing antibodies.

Psoriasis involves immune dysregulation and a lipid-driven mechanism in which FABP5 induces ferroptosis. Blocking FABP5 eases inflammation, pointing to a potential new treatment pathway beyond current treatments.

A new type of CAR T-cell therapy elicits a more controlled immune response to cancer in mice, effectively killing cancer cells with fewer side effects.

PVEK, a CD123-targeting antibody-drug conjugate, demonstrated strong response rates in two studies. Combined with VEN/AZA, it produced high remissions in CD123-positive AML and as monotherapy, it delivered high responses in high-risk BPDCN patients.